1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967; 16:178.
2. Kim GB, Park SH, Eun LY, et al. Epidemiology and clinical features of Kawasaki disease in South Korea, 2012–2014. Pediatr Infect Dis J. 2017; 36:482–485.
3. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017; 135(17):e927–e999.
4. Abrams JY, Belay ED, Uehara R, Maddox RA, Schonberger LB, Nakamura Y. Cardiac complications, earlier treatment, and initial disease severity in Kawasaki disease. J Pediatr. 2017; pii: S0022-3476(17)30655-8. DOI:
10.1016/j.jpeds.2017.05.034. [Epub ahead of print].
5. Lim YJ, Jung JW. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease. Yonsei Med J. 2014; 55:1260–1266.
6. Kato H. Cardiovascular complications in Kawasaki disease: coronary artery lumen and long-term consequences. Prog Pediatr Cardiol. 2004; 19:137–145.
7. Golshevsky D, Cheung M, Burgner D. Kawasaki disease: the importance of prompt recognition and early referral. Aust Fam Physician. 2013; 42:473–476.
8. Suda K, Iemura M, Nishiono H, et al. Long-term prognosis of patients with Kawasaki disease complicated by giant coronary aneurysms: a single-institution experience. Circulation. 2011; 123:1836–1842.
9. Jang GY, Kang IS, Choi JY, et al. Nationwide survey of coronary aneurysms with diameter >6 mm in Kawasaki disease in Korea. Pediatrics Int. 2015; 57:367–372.
10. Bang JS, Kim GB, Kwon BS, et al. Long–term prognosis for patients with Kawasaki disease complicated by a large coronary aneurysm (diameter ≥6 mm). Korean Circ J. 2017; 47:516–522.